AI Engines For more Details: Perplexity Kagi Labs You
Bile Acid Function: Dehydrocholic acid is one of the primary bile acids produced in the liver and stored in the gallbladder. Bile acids, including dehydrocholic acid, play essential roles in emulsifying dietary fats, facilitating lipid digestion, and promoting the absorption of fat-soluble vitamins and nutrients in the small intestine.
Gallstone Dissolution: Dehydrocholic acid has been investigated for its potential therapeutic use in the dissolution of gallstones, particularly cholesterol gallstones. By increasing the solubility of cholesterol in bile, dehydrocholic acid may help dissolve cholesterol gallstones and prevent their recurrence. However, the use of dehydrocholic acid for this purpose has largely been supplanted by other treatments, such as oral bile acid therapy with ursodeoxycholic acid (UDCA) or surgical interventions.
Sodium Deoxycholate Derivative: While dehydrocholic acid itself is not widely used as a therapeutic agent, its sodium salt, sodium deoxycholate, has been employed for various medical and cosmetic purposes. Sodium deoxycholate is known for its detergent and solubilizing properties and has been utilized in the treatment of subcutaneous fat deposits through injection lipolysis procedures.
Injection Lipolysis: Sodium deoxycholate injections have been used off-label for nonsurgical fat reduction and body contouring, particularly in the treatment of localized adiposity, such as submental fat (double chin) and small pockets of fat on the body. The injections are typically administered directly into the targeted fat deposits, where sodium deoxycholate disrupts fat cell membranes, leading to cellular breakdown and eventual elimination of fat.
Adverse Effects: While injection lipolysis with sodium deoxycholate may offer cosmetic benefits, it is associated with potential adverse effects, including pain, swelling, bruising, redness, and induration at the injection site. In some cases, more serious complications, such as skin necrosis, nerve injury, and contour irregularities, may occur. Therefore, the procedure should be performed by trained healthcare professionals in appropriate clinical settings, and patients should be informed of the potential risks and benefits.
Regulatory Status: The use of sodium deoxycholate injections for cosmetic purposes is subject to regulatory oversight in many countries. Providers offering injection lipolysis procedures should adhere to applicable regulations and guidelines to ensure patient safety and quality of care.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium bifidum | Reduces |
| species | Bifidobacterium breve | Reduces |
| species | Bifidobacterium catenulatum | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| species | Veillonella atypica | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Veillonella | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 0 | 1 | Clostridium | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Thomasclavelia | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | Odoribacter | genus | Decreases |
| 0 | 1 | Blautia | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Collinsella | genus | Decreases |
| 0 | 1 | Clostridium perfringens A | no rank | Decreases |
| 0 | 1 | Clostridium perfringens B | no rank | Decreases |
| 0 | 1 | Clostridium perfringens C | no rank | Decreases |
| 0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
| 0 | 1 | Clostridium perfringens D | no rank | Decreases |
| 0 | 1 | Clostridium perfringens E | no rank | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 1 | 0 | Bifidobacterium longum | species | Decreases |
| 1 | 0 | Streptococcus parasanguinis | species | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 0 | 1 | Streptococcus sp. HSISM1 | species | Decreases |
| 0 | 1 | Streptococcus sp. LPB0220 | species | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Veillonella parvula | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Bifidobacterium adolescentis | species | Decreases |
| 1 | 0 | Bacteroides caccae | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Clostridium perfringens | species | Decreases |
| 1 | 0 | Thomasclavelia ramosa | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 1 | 0 | Roseburia hominis | species | Decreases |
| 0 | 1 | Bifidobacterium breve | species | Decreases |
| 0 | 1 | Streptococcus lactarius | species | Decreases |
| 1 | 0 | Odoribacter splanchnicus | species | Decreases |
| 0 | 1 | Veillonella rodentium | species | Decreases |
| 0 | 1 | Streptococcus salivarius | species | Decreases |
| 0 | 1 | Streptococcus sp. FDAARGOS_192 | species | Decreases |
| 1 | 0 | Blautia obeum | species | Decreases |
| 0 | 1 | Streptococcus australis | species | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 0 | 1 | Streptococcus infantis | species | Decreases |
| 0 | 1 | Streptococcus sp. oral taxon 061 | species | Decreases |
| 0 | 1 | Veillonella dispar | species | Decreases |
| 0 | 1 | Streptococcus oralis | species | Decreases |
| 0 | 1 | Veillonella sp. S12025-13 | species | Decreases |
| 0 | 1 | Streptococcus vestibularis | species | Decreases |
| 0 | 1 | Veillonella nakazawae | species | Decreases |
| 0 | 1 | Streptococcus sp. oral taxon 431 | species | Decreases |
| 0 | 1 | Bifidobacterium angulatum | species | Decreases |
| 0 | 1 | Streptococcus ilei | species | Decreases |
| 0 | 1 | Bacteroides luhongzhouii | species | Decreases |
| 0 | 1 | Streptococcus sp. Marseille-Q6470 | species | Decreases |
| 0 | 1 | Veillonella rogosae | species | Decreases |
| 0 | 1 | Streptococcus sp. A12 | species | Decreases |
| 0 | 1 | Streptococcus gordonii | species | Decreases |
| 0 | 1 | Streptococcus intermedius | species | Decreases |
| 0 | 1 | Coprococcus catus | species | Decreases |
| 0 | 1 | Bifidobacterium catenulatum | species | Decreases |
| 0 | 1 | Veillonella atypica | species | Decreases |
| 0 | 1 | Bifidobacterium bifidum | species | Decreases |
| 0 | 1 | Lancefieldella parvula | species | Decreases |
| 0 | 1 | Bacteroides sp. DH3716P | species | Decreases |
| 1 | 0 | Bacteroides ovatus | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Collinsella aerofaciens | species | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.2 | -0.2 | |
| ADHD | 2.1 | 2.1 | |
| Age-Related Macular Degeneration and Glaucoma | 0.1 | 0.2 | -1 |
| Allergic Rhinitis (Hay Fever) | 1.2 | 2.4 | -1 |
| Allergies | 3 | 1.4 | 1.14 |
| Allergy to milk products | 0.5 | 0.7 | -0.4 |
| Alopecia (Hair Loss) | 0.5 | 0.5 | |
| Alzheimer's disease | 2 | 2.9 | -0.45 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.8 | 0.2 | 3 |
| Ankylosing spondylitis | 1.5 | 0.3 | 4 |
| Anorexia Nervosa | 1 | 0.9 | 0.11 |
| Antiphospholipid syndrome (APS) | 0.4 | 0.2 | 1 |
| Asthma | 2.4 | 1.7 | 0.41 |
| Atherosclerosis | 0.5 | 0.6 | -0.2 |
| Atrial fibrillation | 1.2 | 0.8 | 0.5 |
| Autism | 3.7 | 3.6 | 0.03 |
| Autoimmune Disease | 0.6 | 0.5 | 0.2 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.1 | -0.1 | |
| Biofilm | 1.5 | 1.5 | |
| Bipolar Disorder | 0.7 | 0.3 | 1.33 |
| Brain Trauma | 0.6 | 0.5 | 0.2 |
| Breast Cancer | 0.3 | 0.3 | |
| Cancer (General) | 0.5 | 2.1 | -3.2 |
| Carcinoma | 1.7 | 0.8 | 1.13 |
| Celiac Disease | 1.3 | 2 | -0.54 |
| Cerebral Palsy | 1.2 | 0.3 | 3 |
| Chronic Fatigue Syndrome | 1.7 | 2.3 | -0.35 |
| Chronic Kidney Disease | 2.2 | 0.9 | 1.44 |
| Chronic Lyme | 0.7 | 0.2 | 2.5 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.7 | 0.7 | 1.43 |
| Chronic Urticaria (Hives) | 0.7 | 0.2 | 2.5 |
| Coagulation / Micro clot triggering bacteria | 0.5 | 0.5 | 0 |
| Cognitive Function | 0.9 | 0.9 | 0 |
| Colorectal Cancer | 3 | 0.6 | 4 |
| Constipation | 0.1 | 0.2 | -1 |
| Coronary artery disease | 0.3 | 0.6 | -1 |
| COVID-19 | 3.9 | 3.5 | 0.11 |
| Crohn's Disease | 2.6 | 1.4 | 0.86 |
| Cushing's Syndrome (hypercortisolism) | 0.1 | -0.1 | |
| cystic fibrosis | 0.9 | -0.9 | |
| deep vein thrombosis | 0.4 | 0.5 | -0.25 |
| Denture Wearers Oral Shifts | 1.2 | 1.2 | |
| Depression | 5 | 3.6 | 0.39 |
| Dermatomyositis | 0.3 | 0.2 | 0.5 |
| Eczema | 0.8 | 1.2 | -0.5 |
| Endometriosis | 1 | 0.4 | 1.5 |
| Eosinophilic Esophagitis | 0.1 | 0.5 | -4 |
| Epilepsy | 1.4 | 1 | 0.4 |
| erectile dysfunction | 0.4 | 0.2 | 1 |
| Fibromyalgia | 1 | 0.5 | 1 |
| Functional constipation / chronic idiopathic constipation | 1.9 | 1.7 | 0.12 |
| gallstone disease (gsd) | 0.7 | 0.6 | 0.17 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | 0.7 | -0.17 |
| Generalized anxiety disorder | 0.8 | 1.6 | -1 |
| giant cell arteritis | 0.1 | -0.1 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.5 | 0.3 | 4 |
| Graves' disease | 0.8 | 1.1 | -0.38 |
| Gulf War Syndrome | 0.6 | 0.7 | -0.17 |
| Halitosis | 1.1 | 0.3 | 2.67 |
| Hashimoto's thyroiditis | 1.5 | 1.2 | 0.25 |
| Heart Failure | 1.7 | 0.5 | 2.4 |
| hemorrhagic stroke | 0.3 | 0.3 | |
| Hidradenitis Suppurativa | 0.8 | 0.2 | 3 |
| High Histamine/low DAO | 0.5 | 0.2 | 1.5 |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0.2 | 0.5 |
| hyperglycemia | 0.8 | 1 | -0.25 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0 | 0 |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 1.9 | 2.8 | -0.47 |
| Hypothyroidism | 0.1 | 0.3 | -2 |
| Hypoxia | 1.2 | 1.2 | |
| IgA nephropathy (IgAN) | 0.8 | 1.3 | -0.63 |
| Inflammatory Bowel Disease | 3.8 | 3.8 | 0 |
| Insomnia | 1 | 1.2 | -0.2 |
| Intelligence | 0.5 | 0.5 | |
| Intracranial aneurysms | 0.5 | 0 | 0 |
| Irritable Bowel Syndrome | 3.2 | 1.8 | 0.78 |
| ischemic stroke | 1.9 | 0.2 | 8.5 |
| Liver Cirrhosis | 2.9 | 1.9 | 0.53 |
| Long COVID | 2.4 | 2.6 | -0.08 |
| Low bone mineral density | 0.1 | -0.1 | |
| Lung Cancer | 0.5 | 0.4 | 0.25 |
| Mast Cell Issues / mastitis | 0.6 | 0.2 | 2 |
| ME/CFS with IBS | 0.6 | 0.8 | -0.33 |
| ME/CFS without IBS | 0.5 | 1 | -1 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.6 | 0.2 | 7 |
| Metabolic Syndrome | 2.7 | 3.8 | -0.41 |
| Mood Disorders | 5.9 | 3 | 0.97 |
| multiple chemical sensitivity [MCS] | 0.9 | 0.1 | 8 |
| Multiple Sclerosis | 3.5 | 1.9 | 0.84 |
| Multiple system atrophy (MSA) | 1.3 | 0.3 | 3.33 |
| myasthenia gravis | 0.3 | 0.2 | 0.5 |
| neuropathic pain | 1.2 | -1.2 | |
| Neuropathy (all types) | 0.5 | 0.5 | 0 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.4 | 0.4 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.4 | 2.3 | -0.64 |
| NonCeliac Gluten Sensitivity | 0.7 | 0.4 | 0.75 |
| Obesity | 4.1 | 3.3 | 0.24 |
| obsessive-compulsive disorder | 1.9 | 1.7 | 0.12 |
| Osteoarthritis | 1 | 0.8 | 0.25 |
| Osteoporosis | 0.6 | 1.1 | -0.83 |
| pancreatic cancer | 0.7 | 0.3 | 1.33 |
| Parkinson's Disease | 3.4 | 2.2 | 0.55 |
| Polycystic ovary syndrome | 1.9 | 1.5 | 0.27 |
| Postural orthostatic tachycardia syndrome | 0.1 | 0.2 | -1 |
| Premenstrual dysphoric disorder | 0.4 | 0.2 | 1 |
| primary biliary cholangitis | 0.6 | 0.6 | 0 |
| Primary sclerosing cholangitis | 2.4 | 1 | 1.4 |
| Psoriasis | 1.2 | 1 | 0.2 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.4 | 1.2 | 1 |
| Rosacea | 0.7 | 0.2 | 2.5 |
| Schizophrenia | 3.9 | 1.2 | 2.25 |
| scoliosis | 0.2 | -0.2 | |
| Sjögren syndrome | 1.4 | 1 | 0.4 |
| Sleep Apnea | 0.5 | 0.3 | 0.67 |
| Slow gastric motility / Gastroparesis | 0.4 | 0.2 | 1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 0.7 | 0.29 |
| Stress / posttraumatic stress disorder | 1.1 | 0.9 | 0.22 |
| Systemic Lupus Erythematosus | 1.5 | 0.9 | 0.67 |
| Tic Disorder | 0.4 | 0.3 | 0.33 |
| Tourette syndrome | 0.5 | 0.1 | 4 |
| Type 1 Diabetes | 1.5 | 2.1 | -0.4 |
| Type 2 Diabetes | 2.3 | 2.7 | -0.17 |
| Ulcerative colitis | 2.3 | 2.7 | -0.17 |
| Unhealthy Ageing | 2.6 | 0.7 | 2.71 |
| Vitiligo | 0.9 | 0.7 | 0.29 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
